What’s In An Abstract? A Preview Of ASCO Annual Meeting Highlights
Executive Summary
Data supporting first-line use of Lilly's Alimta in non-small cell lung cancer and GlaxoSmithKline's data on combining two targeted oncologics - Tykerb and Herceptin - are among the highlights of the massive data drop from the upcoming American Society of Clinical Oncology annual meeting
You may also be interested in...
Amgen CME Grants Equal 0.4% Of Sales – More Than Pfizer, Less Than Lilly
Educational grants and donations made by the Amgen Medical Education department totaled more than $11 million in the first quarter of 2008, according to an inaugural Web posting May 22
GSK Tykerb Priced At Discount To Herceptin In Metastatic Breast Cancer
GlaxoSmithKline is pricing its breast cancer therapy Tykerb at a slight discount to Genentech's Herceptin (trastuzumab) in the metastatic breast cancer setting
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011